The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/140470
Pharma Management New Trends In Pharma/Bio Executive Compensation By Steve Cornacchia O ver the past several years, the life sciences industry has faced an increasingly challenging environment overall, including stringent regulatory issues, ever-increasing scientific hurdles in new therapeutics R&D;, and an increasingly competitive global marketplace. The global hiring pool for life sciences also has become increasingly competitive. To entice key talent into the fold, companies are offering more aggressive and creative compensation packages. The structure of executive compensation plans has changed broadly over these last four years. Regardless of company size, there is not only a healthy gain in total compensation, but also a significant change in the mix of cash-vs.-equity and stock-vs.-option awards. Companies need to take note in order to remain competitive in recruiting and retaining their most talented leaders. NEW CHANGES FOR REWARDING EXECUTIVES In an analysis of the publicly disclosed executive compensation plans within the U.S. public biotech and pharmaceutical industry, there are several changes that can be tracked in the way executives are being rewarded. These trends can be observed across the spectrum of large corporations with market capitalizations over $10B to small businesses under $250M. Since 2009, these executives have seen an average 20% increase in their overall compensation, mostly driven by increases in variable compensation, including cash incentives and stock and options awards. 42 LifeScienceLeader.com Additionally, it is obvious from the research that life sciences companies are moving away from incentivizing executives with cash bonuses, gravitating much more aggressively towards a mix of equity incentive awards. The percentage of stock to options is increasing, likely reflecting the last several years of stagnant stock performance. Increasing the stock offer in the form of restricted stock units, performance share units, and other nonoption grants in an overall compensation package has become a differentiating offer strategy. These trends are particularly evident with small and midcap companies, organizations that had tended toward stock options as their primary equity driver, but are now moving to stock awards as a major component of their equity incentive. Even microcap companies with market capitalization under $250M are following suit, despite having historically leveraged significant option awards and lower cash compensation. Today, that same group is now compensating executives with an even mix of cash and equity, and the share of stock awards within that equity package has grown significantly. WHY COMPENSATION PACKAGES ARE EVOLVING Fierce competition for skilled, experienced, and successful senior executives is forcing life sciences companies to offer compensation packages that grow Cash Vs. Equity Compensation July 2013